Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223617 | 1.00 | FKBP1A (0.58) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL1401256 | 1.00 | FKBP1A (0.58) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL24358344 | 0.96 | FKBP1A (0.64) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL15893182 | 0.96 | FKBP1A (0.64) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL444202 | 0.96 | FKBP1A (0.64) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL1088066 | 0.90 | FKBP1A (0.52) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL16774272 | 0.89 | KMT2A (0.52) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL3206028 | 0.88 | HSD17B10 (0.54) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL4962228 | 0.88 | HSD17B10 (0.54) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL9933627 | 0.87 | HSD17B10 (0.53) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-12-17 | — | — | US | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| CN-101168514-A | Practical synthesis method for alpha-aminosuberate and alpha-amino suberic acid monoester with optical activity | SHANGHAI PHARMATECH CO LTD (CN) | 2008-04-30 | — | — | CN | disclosed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| EP-1537106-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2005-06-08 | — | — | EP | disclosed |
| CN-1178936-C | Sulfonyl-pyrrolidine derivatives useful for treatment of neurological disorders | - | 2004-12-08 | — | — | CN | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | disclosed |
| CN-1440405-A | Sulfonyl-pyrrolidine derivatives useful for treatment of neurological disorders | HOFFMANN LA ROCHE (CH) | 2003-09-03 | — | — | CN | disclosed |
| EP-1100824-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001726-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | FKBP1A 570/4885MEN1 2012/4885KMT2A 1466/4885 |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | FKBP1A 570/4885MEN1 2012/4885KMT2A 1466/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | FKBP1A 3305/4885MEN1 2502/4885KMT2A 3816/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | FKBP1A 451/4885MEN1 2884/4885KMT2A 391/4885 |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | CNKSR1, RB1, AR | FKBP1A 2521/4885MEN1 1757/4885KMT2A 1195/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | FKBP1A 2000/4885MEN1 1822/4885KMT2A 872/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | FKBP1A 1373/4885MEN1 3826/4885KMT2A 3396/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | FKBP1A 451/4885MEN1 2884/4885KMT2A 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.